AVBP Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $17,999,982.00
Insider Selling (Last 12 Months): $0.00

ArriVent BioPharma Insider Trading History Chart

This chart shows the insider buying and selling history at ArriVent BioPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ArriVent BioPharma Share Price & Price History

Current Price: $21.70
Price Change: Price Increase of +0.16 (0.74%)
As of 03/1/2024 02:38 PM ET

This chart shows the closing price history over time for AVBP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.

ArriVent BioPharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2024Hillhouse Investment ManagemenMajor ShareholderBuy555,555$18.00$9,999,990.004,484,672View SEC Filing Icon  
1/30/2024Orbimed Advisors LlcDirectorBuy444,444$18.00$7,999,992.001,513,664View SEC Filing Icon  
See Full Table
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.

SEC Filings (Institutional Ownership Changes) for ArriVent BioPharma (NASDAQ:AVBP)

ArriVent BioPharma logo
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Read More on ArriVent BioPharma

Today's Range

Now: $21.70
Low: $21.11
High: $22.20

50 Day Range

MA: N/A

52 Week Range

Now: $21.70
Low: $18.37
High: $25.95

Volume

83,630 shs

Average Volume

181,062 shs

Market Capitalization

$693.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of ArriVent BioPharma?

ArriVent BioPharma's top insider investors include:
  1. Hillhouse Investment Managemen (Major Shareholder)
  2. Orbimed Advisors Llc (Director)
Learn More about top insider investors at ArriVent BioPharma.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.